Biotech Startups

Phycin develops engineered growth factors designed for higher stability and performance, including a thermostable recombinant basic fibroblast growth factor (bFGF) that remains active for 21+ days at 37°C. Its products target researchers and clinicians working in regenerative medicine, cell culture, and related life science applications.

2 investors

Phyco Bloom uses synthetic biology to engineer algae that capture carbon dioxide and convert it into oil for use as a sustainable fuel or plastic feedstock. The company targets applications such as aviation, shipping, and materials production.

2 investors

Phyla develops a patented phage-based skincare treatment that targets acne-causing C. acnes bacteria while preserving the skin's barrier and microbiome. It markets its products to consumers and offers a professional program for licensed skin professionals and healthcare practitioners.

2 investors

Phylos develops elite, phenotypically-stable, fully-feminized F1 hybrid cannabis seeds designed to give growers uniform, high-THC plants with agronomic traits that reduce production costs. The company serves cannabis cultivators of all sizes as an alternative to clonal propagation.

2 investors

Pictor Diagnostics develops a proteomics platform that enables researchers, diagnostics manufacturers, clinical labs, and veterinary clinics to perform multi-marker protein testing across diverse sample types. The platform combines an affordable instrument and assays that integrate into existing lab workflows without requiring specialized equipment or training.

2 investors

Pictor Labs develops virtual staining technologies for pathology laboratories, generating additional insight from existing tissue specimens and slides while preserving tissue utility and fitting into current lab workflows. The company serves clinical and research pathology labs in the life sciences and healthcare space.

2 investors

Piezotx develops Piezopen, a drug delivery platform that combines piezoelectric pulses with microneedle electrodes to deliver "naked" RNA and DNA without lipid nanoparticles or viral vectors. The company partners with startups and pharmaceutical companies on genetic medicines across infectious disease vaccines, immuno-oncology, chronic disease, and dermatology.

2 investors

Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics. Its oncoReveal portfolio of RUO and IVD oncology panels covers solid tumors, hematologic cancers, and liquid biopsy, aiming to deliver faster, lower-cost genomic testing for precision medicine.

2 investors

PinotBio is a biotechnology company developing novel anticancer treatments, including its PINOT-ADC antibody-drug conjugate platform and the PBX-001 drug candidate. It focuses on cancer therapy within the biotech and drug development industry.

2 investors

PipeBio provides a bioinformatics platform for drug discovery that enables scientists and bioinformaticians to analyze genomic and assay data. The platform combines sequence data management, machine learning tools, and visualization capabilities to accelerate therapeutic development for academia, biotech companies, and pharmaceutical firms.

2 investors

Pitri uses synthetic biology to engineer fungi that produce colorants intended as alternatives to petroleum-derived dyes. The pigments are aimed at manufacturers of cosmetics, packaging, and paints looking for non-toxic, bio-based options.

2 investors

Pixelgen develops DNA-based visualization technology for cell-surface proteomics, enabling nanoscale spatial analysis of immune cell proteins for precision medicine and translational research. The company's Proximity Network Assay platform supports applications in immunology, hematology, and cell therapy diagnostics and therapeutics.

2 investors

Pixium Vision SA developed the PRIMA System, an implantable device for treating late-stage macular degeneration, and ran clinical trials in Europe. Its assets, including the ongoing clinical trials, have been acquired by Science Corporation.

2 investors

Plantee develops renewable-based bio products and biocomposites from waste and by-product streams sourced from forestry, agriculture, and marine ecosystems to replace fossil inputs in consumer products. The company targets the emerging circular bioeconomy market in Canada.

2 investors

Plantik develops plant engineering technologies that use genomic data and biotechnology to tap into underexplored genetic variation and create climate-resilient crops, with an initial focus on thermotolerant plants that withstand heat stress. It targets challenges around harvest yield, seed availability, and food security.

2 investors

Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays. It targets clinical genomics applications such as oncology to support AI-driven precision medicine.

2 investors

Pluto Bio provides a cloud-based, AI-native platform for multi-omics data analysis and program management, letting scientists organize experiments, run transcriptomics, proteomics, spatial, and single-cell analyses, and generate publication-ready visualizations without coding. It serves pharma and translational science teams, academic research labs, and CROs, and spun out of Harvard's Wyss Institute.

2 investors

POC Pharma offers a data analytics solution that combines its proprietary pharmaceutical data with clients' existing datasets to guide customer segmentation, sales targeting, and marketing decisions. The tools help pharmaceutical commercial teams assess promotion ROI, identify growth opportunities, and allocate resources across customer segments and channels.

2 investors

Polaris Partners is a venture capital firm that partners with and invests in biotech and healthcare entrepreneurs building companies in those sectors.

2 investors

POLARISqb combines quantum computing, genetics, and molecular chemistry to design novel drugs for previously undruggable diseases. The company targets pharmaceutical development using advanced computational methods to accelerate drug discovery.

2 investors

PolyPid is a biopharmaceutical company developing long-acting, controlled-release medicines delivered at the site of care, with a lead product D-PLEX100 using its proprietary Kynatrix technology for preventing surgical site infections. Its pipeline targets surgical care, metabolic diseases, and other therapeutic areas.

2 investors

Portal Biotech develops bench-top instruments that use nanopore biosensors coupled with machine learning to detect, sequence, and characterise single protein and metabolite molecules, revealing modifications, mutations, and isoforms. The technology, spun out of the Maglia Lab at the University of Groningen, serves academic research, biopharmaceutical, biotechnology, and industrial labs for proteomic and metabolomic analysis.

2 investors

Powerhouse.bio is a biotechnology company that combines experimental biology with applied machine learning. The company works at the intersection of biology and computational science.

2 investors

ProtaGene provides molecular bioanalytical services for gene therapy development, specializing in biodistribution studies, transgene expression assessment, and vector shedding analysis to support preclinical safety evaluation and clinical development of viral vector-based therapies.

2 investors